Keywords: Public Citizen Johnson & Johnson, Bedaquiline, Tuberculosis, Risks, USA
Public Citizen urges FDA to reject accelerated approval for Janssen's bedaquiline
Article | 27 December 2012
The US Food and Drug Administration should not approve the anti-tuberculosis drug bedaquiline from Janssen, a unit of health care ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
